BioCryst Pharmaceuticals Inc
BCRX8.340USD
+0.390+4.91%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.74BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über BioCryst Pharmaceuticals Inc Unternehmen
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Unternehmensinformationen
BörsenkürzelBCRX
Name des UnternehmensBioCryst Pharmaceuticals Inc
IPO-datumMar 04, 1994
CEOMr. Charles K. Gayer
Anzahl der mitarbeiter580
WertpapierartOrdinary Share
GeschäftsjahresendeMar 04
Addresse4505 Emperor Blvd Ste 200
StadtDURHAM
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl27703-8457
Telefon19198591302
Websitehttps://www.biocryst.com/
BörsenkürzelBCRX
IPO-datumMar 04, 1994
CEOMr. Charles K. Gayer
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
89.76K
+16.18%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
40.33K
+44.91%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 12
Aktualisiert: Sat, Jul 12
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
32.45%
Investment Advisor/Hedge Fund
29.96%
Hedge Fund
18.97%
Research Firm
3.20%
Private Equity
1.84%
Individual Investor
1.27%
Pension Fund
0.53%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Other
11.14%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
549
185.97M
88.87%
-12.50M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
2023Q1
554
177.87M
94.17%
-5.12M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
21.61M
10.33%
-230.66K
-1.06%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.89M
8.55%
+189.84K
+1.07%
Mar 31, 2025
Kynam Capital Management LP
8.93M
4.27%
-156.84K
-1.73%
Mar 31, 2025
Avoro Capital Advisors LLC
8.70M
4.16%
-3.17M
-26.68%
Mar 31, 2025
State Street Global Advisors (US)
7.81M
3.73%
+314.44K
+4.19%
Mar 31, 2025
Alkeon Capital Management LLC
6.00M
2.87%
+109.73K
+1.86%
Mar 31, 2025
Two Sigma Investments, LP
5.27M
2.52%
+992.22K
+23.22%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
2.48%
-2.95M
-36.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.96M
2.37%
+136.90K
+2.84%
Mar 31, 2025
RP Management, LLC
3.85M
1.84%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
3.3%
Invesco Biotechnology & Genome ETF
2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
1.83%
Virtus LifeSci Biotech Products ETF
1.66%
ALPS Medical Breakthroughs ETF
1.27%
SPDR S&P Biotech ETF
0.68%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Main Thematic Innovation ETF
0.58%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Invesco NASDAQ Future Gen 200 ETF
0.38%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil3.3%
Invesco Biotechnology & Genome ETF
Anteil2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil1.83%
Virtus LifeSci Biotech Products ETF
Anteil1.66%
ALPS Medical Breakthroughs ETF
Anteil1.27%
SPDR S&P Biotech ETF
Anteil0.68%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.66%
Main Thematic Innovation ETF
Anteil0.58%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.39%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.38%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
